01 July 2022 : Case report
Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Trevor Persaud1ABCDEFG*, Richard Morgan 1ABCDEFG, Hein Linn Thant1ABCDEFG, Francis J. DeAsis 1ABCDEFG, Felix Ferre1DEFG, Jose Diaz 1BDEFDOI: 10.12659/AJCR.936600
Am J Case Rep 2022; 23:e936600
Table 2. Patient’s laboratory tests summary (obtained on initial visit).
Test | Result | Reference range |
---|---|---|
Completement, total | >60 | 31–60 U/mL |
Completement component C3 | 156 | 82–185 mg/dL |
Completement component C4 | 36 | 15–53 mg/dL |
Rheumatoid factor | ||
C-reactive protein | 2.2 | |
Sjogren’s antibody (SS-A) | ||
Sjogren’s antibody (SS-B) | ||
Proteinase-3 antibody | ||
Myeloperoxidase antibody | ||
HLA-B27 antigen | 6.9 (Negative) | 5.0–11.0 mcg/mL |
ANA screen, IFA | Negative | Negative |
HIV antigen/antibody, 4 generation | Non-reactive | Non-reactive |
Hepatitis C antibody | Non-reactive | Non-reactive |
Cyclic citrullinated peptide antibody | ||
VDRL | Non-Reactive | Non-reactive |
Red blood cell count | 4.18 | 4.20–5.80 Million/uL |
Hemoglobin | 12.7 | 13.2–17.1 g/dL |
Hematocrit | 35.4 | 38.5–50.0% |
Glucose | 115 | 65–99 mg/dL |
SS-A – anti-Sjogren’s-syndrome-related antigen A autoantibodies; SSB – anti-Sjögren’s-syndrome-related antigen B autoantibodies; HLA – human leukocyte antigens; ANA – antinuclear antibodies; IFA – immunofluorescence assay; HIV – human immunodeficiency virus; VDRL – venereal disease research laboratory test. |